-
Evaluation of the Inflammation-blocking Drug Tolebrutinib as a Novel Disease-modifying Therapeutic for Parkinson's Disease
… the effectiveness of Tolebrutinib in cell culture and in multiple preclinical animal models of PD. We will determine … shown to be safe and well-tolerated in clinical trials for multiple sclerosis. If this project is successful, … … Neuroprotective/Regenerative … peripheral immune system … Therapeutic Pipeline Program … Richard Gordon, PhD, …
-
Effects of noradrenergic or serotoninergic system lesions combined with NS lesions on rodent models of 'non-motor'-like symptoms
… little attention. Damage to all these neuronal systems would contribute to comorbid anxiety, depression and …
-
Clinical Evaluation of LRRK2 Inhibitors on Inflammatory Responses in Crohn's and Parkinson's Diseases
… in CD and PD. … LRRK2 … Inflammation … LRRK2 in the Immune System … Tsuneya Ikezu, MD//PhD …
-
Interrogating LRRK2 Variants Common in Asian Populations to Discover Unique Biomarkers for Parkinson’s Disease
… effects these variants have on cellular processes and systems, including the immune and gastrointestinal systems. We further hypothesize that these biomarkers will … whether, and how, these variants influence the immune system, the lysosomal system (responsible for removing …
-
Genetic Screening and Functional Analysis of Factors Regulating Dopaminergic Development and Survival in C. elegans and mammalian systems
-
Assessing Inhibition of a Protein of the “Complement System” to Reduce Brain Inflammation and Neuronal Loss in People with Parkinson’s Disease